We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Continuous Glucose Monitoring Sensors Compared for Effectiveness

By LabMedica International staff writers
Posted on 01 Oct 2014
A continuous glucose monitor, a tool used in optimizing glycemic control in patients with type 1 diabetes, is a subcutaneous tissue sensor that provides an interstitial fluid glucose measurement every one to five minutes.

The simultaneous use of two popular continuous glucose monitoring (CGM) sensors revealed clear differences in their accuracy and in patient-rated treatment experiences, including ease of use, feelings of safety, and willingness to use the system in daily life.

Scientists at the University of Gothenburg (Sweden) working with their North American colleagues enrolled 38 patients who met the inclusion criteria for the study. More...
The mean age was 50 years, 66% were men, and mean diabetes duration was 22.9 years. The mean HbA1c level was 58.9 mmol/mol or 7.5%. Patients were educated on how to use the CGM sensors, and the sensors were calibrated. All participants were educated on use of the HemoCue (Ängelholm, Sweden) analyzer and cuvettes and were advised to measure capillary glucose values six to 10 times per day.

The 38 ambulatory patients with type 1 diabetes used the Dexcom G4 PLATINUM (San Diego, CA, USA) and the Enlite Guardian REAL-Time System (Medtronic MiniMed, Inc.; Northridge, CA, USA) CGM sensors simultaneously for a minimum of four and maximum of six days. The mean absolute relative difference (MARD) in blood glucose for the Dexcom G4 was significantly lower (13.9%) than for the Enlite sensor (17.8%) among a total of 1,012 sets of measurements. For glucose levels in the hypoglycemic range of less than 4.0 mmol/L, the MARD for the Dexcom G4 was 20.0% compared with 34.7% for the Enlite. More patients rated their experience with the Dexcom G4 as positive and preferred to use it in their daily lives.

The authors concluded that the Dexcom G4 CGM system showed greater accuracy than the Enlite system, and patients had a significantly more positive treatment experience. The findings indicate that the Dexcom G4 is more optimal when dosing insulin, when taking other treatment actions, and in avoiding hypoglycemia. The results also indicate that the Dexcom G4 may make it possible for more patients to wear a CGM device for a longer period of time. These findings should be considered by treatment providers when recommending suitable CGM systems and evaluating ongoing therapies. The study was published on September 18, 2014, in the journal Diabetes Technology & Therapeutics.

Related Links:

University of Gothenburg
HemoCue
Dexcom



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
New
Giardia Assay
AccuDiag Giardia
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.